196 related articles for article (PubMed ID: 36297430)
1. Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux.
Čermáková L; Hofman J; Laštovičková L; Havlíčková L; Špringrová I; Novotná E; Wsól V
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297430
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
Morell A; Budagaga Y; Vagiannis D; Zhang Y; Laštovičková L; Novotná E; Haddad A; Haddad M; Portillo R; Hofman J; Wsól V
Arch Toxicol; 2022 Dec; 96(12):3265-3277. PubMed ID: 35972551
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.
Sorf A; Novotna E; Hofman J; Morell A; Staud F; Wsol V; Ceckova M
Biochem Pharmacol; 2019 May; 163():290-298. PubMed ID: 30826329
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.
Morell A; Čermáková L; Novotná E; Laštovičková L; Haddad M; Haddad A; Portillo R; Wsól V
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322571
[TBL] [Abstract][Full Text] [Related]
6. Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating paclitaxel resistance in breast cancer MCF7 cells.
Matsunaga T; Horinouchi M; Saito H; Hisamatsu A; Iguchi K; Yoshino Y; Endo S; Ikari A
J Biochem; 2023 Mar; 173(3):167-175. PubMed ID: 36413758
[TBL] [Abstract][Full Text] [Related]
7. Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
Tavares TS; Hofman J; Lekešová A; Želazková J; Wsól V
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114555
[TBL] [Abstract][Full Text] [Related]
8. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
[TBL] [Abstract][Full Text] [Related]
9. Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Matsunaga T; Okumura N; Saito H; Morikawa Y; Suenami K; Hisamatsu A; Endo S; Ikari A
Chem Biol Interact; 2020 Dec; 332():109295. PubMed ID: 33096057
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
Morell A; Novotná E; Milan J; Danielisová P; Büküm N; Wsól V
Arch Toxicol; 2021 Jan; 95(1):67-78. PubMed ID: 33025066
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
13. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
14. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme.
Vagiannis D; Yu Z; Novotna E; Morell A; Hofman J
Biochem Pharmacol; 2020 Aug; 178():114061. PubMed ID: 32497550
[TBL] [Abstract][Full Text] [Related]
15. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
16. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cihalova D; Staud F; Ceckova M
Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
[TBL] [Abstract][Full Text] [Related]
17. Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme.
Vagiannis D; Novotna E; Skarka A; Kammerer S; Küpper JH; Chen S; Guo L; Staud F; Hofman J
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32231067
[TBL] [Abstract][Full Text] [Related]
18. VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Teng QX; Chen ZS; Kong D; Yang DH
Front Pharmacol; 2018; 9():1236. PubMed ID: 30425643
[TBL] [Abstract][Full Text] [Related]
19. Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Matsunaga T; Saito H; Endo S; Iguchi K; Soda M; El-Kabbani O; Hara A; Ikari A
Free Radic Res; 2016 Dec; 50(12):1296-1308. PubMed ID: 27629782
[TBL] [Abstract][Full Text] [Related]
20. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
